Analyst firms · Guggenheim · NMRA

Guggenheim NMRA price target and rating history

Neumora Therapeutics Inc. (NMRA) · Health Care

Guggenheim rates Neumora Therapeutics Inc. (NMRA) Buy with a $14 price target, as of its latest action on Oct 27, 2025. It has published 3 rating actions on NMRA since October 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a NMRA price target in the last 12 months, the median target is $7.

Current rating
Buy
Price target
$14
Median target, all firms
$7
Actions on NMRA
3

Guggenheim price target on NMRA

$22$18$14202420252026
Guggenheim price target on NMRA, each point a stated target, October 2023 to October 2025.

Every Guggenheim rating on NMRA

How other firms rate NMRA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$7Jun 16, 2026
NeedhamBuy$5Jun 16, 2026
William BlairOutperformFeb 17, 2026
Leerink PartnersOutperform$8Jan 12, 2026
RBC Capital MarketsOutperform$7Dec 1, 2025

Questions about Guggenheim and NMRA

What is Guggenheim's price target for NMRA?
Guggenheim's latest stated price target for Neumora Therapeutics Inc. (NMRA) is $14, from its action on Oct 27, 2025.
What is Guggenheim's rating on NMRA?
Guggenheim rates NMRA Buy, a bullish rating, as of Oct 27, 2025.
When did Guggenheim last change its view on NMRA?
On Oct 27, 2025, Guggenheim upgrades to Buy from Neutral, price target $14.
How does Guggenheim's NMRA target compare with other analysts?
Across 4 firms with a NMRA price target in the last 12 months, the median target is $7.

More NMRA rating histories

All Guggenheim ratingsNMRA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.